| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Neurology and MR Institute, Karl-Franzens University, Graz, Austria.
To test the reliability of four previously proposed MRI criteria for the diagnosis of MS, we reviewed 1,500 consecutive brain scans for the presence, number, size, and location of areas of increased signal (AIS) on proton-density and T2-weighted images, unaware of the patients' clinical presentations and ages. This series included 134 subjects with a clinical diagnosis of MS. Relying exclusively on the presence of at least three or four AIS for a positive diagnosis of MS resulted in high sensitivity (90% for three AIS and 87% for four) but inadequate specificity (71% for three AIS and 74% for four) and positive predictive value (23% for three AIS and 25% for four). If one of these lesions was required to border the lateral ventricles, specificity was 92% and positive predictive value was 50% at a sensitivity of 87%. Using the Fazekas criteria (at least three AIS and two of the following features: abutting body of lateral ventricles, infratentorial lesion location, and size <5 mm) led to a further highly significant improvement of specificity (96%; p = 0.0000) and increase of the positive predictive value (65%) at the expense of a less significant decrease in sensitivity (81%; p <0.01).
Address correspondence and reprint requests to Dr. Franz Fazekas, Department of Neurology, Karl-Franzens University, Auenbruggerplatz 22, A-8036 Graz, Austria.
Received June 3, 1992. Accepted for publication in final form September 22, 1992.
This article has been cited by other articles:
|
|
 |
|
  P. Soelberg Sorensen, J. Haas, F. Sellebjerg, T. Olsson, M. Ravnborg, and the TARIMS Study Group IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS Neurology, December 14, 2004; 63(11): 2028 - 2033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Hahn, M. M. Shroff, S. I. Blaser, and B. L. Banwell MRI criteria for multiple sclerosis: Evaluation in a pediatric cohort Neurology, March 9, 2004; 62(5): 806 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kalanie, K. Gharagozli, and A. R. Kalanie Multiple sclerosis: report on 200 cases from Iran Multiple Sclerosis, February 1, 2003; 9(1): 36 - 38. [Abstract] [PDF]
|
|
|
|
|
|
A. van der Meijs, I. Tan, and F. Barkhof Incidence of enhancement of the trigeminal nerve on MRI in patients with multiple sclerosis Multiple Sclerosis, September 1, 2002; 8(1_suppl): 64 - 67. [Abstract] [PDF]
|
|
|
|
|
|
A H. van der Meijs, I L Tan, and F Barkhof Incidence of enhancement of the trigeminal nerve on MRI in patients with multiple sclerosis Multiple Sclerosis, February 1, 2002; 8(1): 64 - 67. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Belopitova, V. Guergueltcheva, and V. Bojinova Definite and Suspected Multiple Sclerosis in Children: Long-Term Follow-up and Magnetic Resonance Imaging Findings J Child Neurol, May 1, 2001; 16(5): 317 - 324. [Abstract] [PDF]
|
|
|
|
|
|
P. Cabre, O. Heinzlef, H. Merle, G.G. Buisson, O. Bera, R. Bellance, J.C. Vernant, and D. Smadja MS and neuromyelitis optica in Martinique (French West Indies) Neurology, February 27, 2001; 56(4): 507 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Kalanie, M Kamgooyan, H Sadeghian, and A R Kalanie Histocompatibility antigen (HLA) associations with multiple sclerosis in Iran Multiple Sclerosis, October 1, 2000; 6(5): 317 - 319. [Abstract] [PDF]
|
|
|
|
|
|
G. S. Gronseth and E. J. Ashman Practice parameter: The usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology, May 9, 2000; 54(9): 1720 - 1725. [Full Text] [PDF]
|
|
|
|
|
|
M Kremenchutzky, D Lee, G P A Rice, and G C Ebers Diagnostic brain MRI findings in primary progressive multiple sclerosis Multiple Sclerosis, April 1, 2000; 6(2): 81 - 85. [Abstract] [PDF]
|
|
|
|
|
|
I L Tan, G J L. Nijeholt, C H Polman, H J Ader, F Barkhof, and the 95 Line 146/147 Study Group Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials Multiple Sclerosis, April 1, 2000; 6(2): 99 - 104. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Tintoré, A. Rovira, M. J. Martínez, J. Rio, P. Díaz-Villoslada, L. Brieva, C. Borrás, E. Grivé, J. Capellades, and X. Montalban Isolated Demyelinating Syndromes: Comparison of Different MR Imaging Criteria to Predict Conversion to Clinically Definite Multiple Sclerosis AJNR Am. J. Neuroradiol., April 1, 2000; 21(4): 702 - 706. [Abstract] [Full Text]
|
|
|
|
|
|
F. Fazekas, F. Barkhof, M. Filippi, R. I. Grossman, D. K. B. Li, W. I. McDonald, H. F. McFarland, D. W. Paty, J. H. Simon, J. S. Wolinsky, et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis Neurology, August 1, 1999; 53(3): 448 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Khoury and H. L. Weiner Multiple Sclerosis: What Have We Learned From Magnetic Resonance Imaging Studies? Arch Intern Med, March 23, 1998; 158(6): 565 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L Frederiksen and C. J. Sindic Intrathecal synthesis of virus-specific oligoclonal IgG, and of free kappa and free lambda oligoclonal bands in acute monosymptomatic optic neuritis. Comparison with brain MRI Multiple Sclerosis, February 1, 1998; 4(1): 22 - 26. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
